Treatment Guides

Why radiotherapy is sometimes used in thalassemia: extramedullary hematopoiesis and spinal cord compression

A referral to radiation oncology can be confusing for someone whose established diagnosis is thalassemia. In a small subset of patients, blood-forming tissue develops outside the bone marrow and forms masses that interfere with nearby structures. Local radiation may be considered when such tissue causes a significant problem. The referral does not, by itself, mean a second diagnosis of cancer. It also does not mean that radiation can correct the inherited cause of thalassemia. The purpose is to address a specific complication. Aydinok et al.: Other Complications, TIF 2025

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Quick answer

A referral to radiation oncology can be confusing for someone whose established diagnosis is thalassemia. In a small subset of patients, blood-forming tissue develops outside the bone marrow and forms masses that interfere with nearby structures. Local radiation may be considered when such tissue causes a significant problem. The referral does not, by itself, mean a second diagnosis of cancer. It also does not mean that radiation can correct the inherited cause of thalassemia. The purpose is to address a specific complication. Aydinok et al.: Other Complications, TIF 2025

Full guide

A referral to radiation oncology can be confusing for someone whose established diagnosis is thalassemia. In a small subset of patients, blood-forming tissue develops outside the bone marrow and forms masses that interfere with nearby structures. Local radiation may be considered when such tissue causes a significant problem. The referral does not, by itself, mean a second diagnosis of cancer. It also does not mean that radiation can correct the inherited cause of thalassemia. The purpose is to address a specific complication. Aydinok et al.: Other Complications, TIF 2025

What the term extramedullary hematopoiesis means

Thalassemia can drive persistent attempts to produce more red cells. Some blood-forming activity may occur outside its usual marrow location, a process called extramedullary hematopoiesis, or EMH. The liver and spleen can be involved, and less commonly discrete masses develop elsewhere. A report may describe these as pseudotumors because of their appearance. That word is not a diagnosis of malignant cancer. TIF 2023: Ineffective Erythropoiesis and Anaemia in NTDTTIF 2023: Extramedullary Haematopoiesis in NTDT

The wording of an imaging report still matters. A lesion that is considered compatible with EMH is not necessarily a lesion with a fully settled diagnosis. Ask how strongly the history and imaging support that conclusion and whether an alternative explanation would change management. A known blood disorder supplies useful context, but cannot explain every new mass without assessment.

A change in walking or bladder function requires urgent attention

Tissue close to the spine can extend into the spinal canal and compress the cord. New or worsening leg weakness, altered sensation, difficulty walking, or a change in bladder or bowel control needs immediate local medical assessment. Do not wait for an international appointment or assume that new difficulty standing is simply the familiar tiredness of anemia. Delay can affect the possibility of neurological recovery. TIF 2023: Extramedullary Haematopoiesis in NTDT

Tell the receiving team when the problem started, whether pain preceded weakness, and what the person can no longer do independently. A short account of walking, transfers, and urinary function often communicates progression better than a general statement about feeling unwell. Collecting a history should not delay emergency care, and someone with unstable balance should not be asked to perform risky exercises to demonstrate the problem.

Imaging must establish the relationship to the spinal cord

MRI is particularly useful when spinal cord compression is suspected. The relevant questions include the spinal levels involved, the extent of tissue within the canal, and its effect on neurological structures. Previous images allow clinicians to distinguish an established abnormality from a changing or newly developed lesion. A report alone may leave out details needed for local treatment planning. TIF 2023: Extramedullary Haematopoiesis in NTDT

Back pain may also have another explanation. Bone disease, fragility, and vertebral abnormalities deserve attention in thalassemia, so an EMH finding should not automatically close the diagnostic discussion. When the symptoms and images do not match well, ask what additional assessment is needed and which problem the proposed treatment is expected to relieve. Casale et al.: Growth Abnormalities, Endocrine, and Bone Disease, TIF 2025

A biopsy decision depends on what remains uncertain

Doctors may recognize a characteristic pattern from imaging and clinical history without obtaining tissue. Blood-forming masses can be highly vascular, making sampling hazardous. Conversely, an atypical lesion may leave a consequential diagnostic uncertainty that cannot simply be ignored. Whether to sample, and how to do so, should reflect both the value of the answer and the anatomical risks. Aydinok et al.: Other Complications, TIF 2025

Useful questions include: what supports EMH, which competing diagnosis remains plausible, and how would a tissue result change treatment? These questions help clarify why a team recommends observation, further imaging, or an invasive procedure. If the cord is threatened, the need for diagnostic confidence must be considered alongside the urgency of protecting neurological function.

An incidental mass does not always require immediate local treatment

An asymptomatic finding in a location that does not threaten important structures may be monitored. A monitoring plan should identify the responsible clinician, the imaging comparison to be used, and symptoms that require earlier review. Size alone cannot define safety across every anatomical site. A relatively small lesion in a confined space can have a different significance from a larger lesion elsewhere. Aydinok et al.: Other Complications, TIF 2025

The hematologist may also reconsider the underlying anemia. Non-transfusion-dependent thalassemia does not mean that transfusion will never be appropriate. A change in complications or clinical circumstances can alter the balance. Ask whether a proposed transfusion course is intended as temporary support for the present complication or a longer change in management, and when that decision will be reviewed. TIF 2023: Ineffective Erythropoiesis and Anaemia in NTDT

Transfusion support and local treatment have different jobs

Improving anemia can reduce the stimulus for compensatory blood formation. However, a response to transfusion may be too slow or incomplete to resolve an acute neurological threat. The team may therefore combine blood support with radiation or a decompressive procedure rather than relying on one intervention to solve every aspect of the problem. The order depends on the clinical situation. TIF 2023: Extramedullary Haematopoiesis in NTDT

If more transfusions are planned, provide previous red-cell antibody findings, transfusion reaction records, and any history of difficulty obtaining compatible blood. Established compatibility precautions remain relevant during an unusual complication. A forthcoming radiation appointment is not a reason to cancel prescribed blood support independently. The blood bank and treating clinicians need a shared plan. Shah, Wood and Maggio: Blood Transfusion, TIF 2025

What radiation is intended to achieve

EMH tissue is sensitive to radiation. Treating the involved area can suppress or reduce tissue that is causing compression, potentially allowing symptoms to improve. Planning takes account of the target, the spinal cord and other nearby organs, prior irradiation, and the patient's age. Published schedules are examples of individual management, not instructions that a patient can select from a list. Saini et al.: Conformal radiation for extramedullary hematopoiesis, five-patient case series, Radiation Oncology, October 2025

The inherited blood disorder persists after successful local treatment. An improvement in leg strength does not establish that transfusion or iron management is no longer needed. Keep the completed radiation record, including the actual site, dates, total dose, and fractions. These details can become essential if a future clinician must assess another lesion close to the previously treated area.

What recent reports can and cannot tell a patient

A 2025 case report described an adolescent with thalassemia-associated EMH and cord compression who improved after radiation combined with transfusion and other medication. It illustrates a possible nonsurgical pathway under particular circumstances. Because several treatments were used, the report cannot isolate the contribution of radiation or forecast another patient's speed of recovery. Reihanian et al.: Radiotherapy for spinal cord compression from EMH, Oxford Medical Case Reports, May 2025

A separate five-patient series published in 2025 reported clinical and imaging responses following conformal radiation. The individual accounts were not identical: recovery varied, and one patient developed EMH at other sites. These details matter when reading an encouraging abstract. A small uncontrolled series cannot establish a universal success rate, the best machine, or the optimal schedule for every lesion. Saini et al.: Conformal radiation for extramedullary hematopoiesis, five-patient case series, Radiation Oncology, October 2025

Why a surgical opinion may still be needed

Severe or rapidly changing neurological compromise, diagnostic uncertainty, or an inadequate response to other treatment may prompt assessment for decompression. Surgery can directly relieve a mechanical problem and may provide tissue for diagnosis. Its risks depend on factors such as vascularity, the extent of involvement, anemia, and spinal stability. Diffuse disease can make a seemingly straightforward removal much more complicated. TIF 2023: Extramedullary Haematopoiesis in NTDT

If specialists propose different approaches, ask them to identify the actual point of disagreement. Is it urgency, the probability of bleeding, confidence in the diagnosis, or the expected neurological benefit? Patients should not have to choose between specialties on the basis of which treatment sounds more advanced. A coordinated plan should identify who makes the next decision and what finding would trigger a change. TIF 2025: Multidisciplinary Care and Reference Centres

Blood counts and general health remain part of the radiation course

During treatment, clinicians may need to watch blood counts and symptoms more closely. The radiation field, baseline anemia, accompanying medication, and clinical response all affect supportive care. Fatigue should be assessed in context rather than automatically attributed to radiation injury. Equally, improving pain should not distract from a new fever or a substantial deterioration in general condition. The recent small radiation series reinforces the need to assess more than the scan alone. Saini et al.: Conformal radiation for extramedullary hematopoiesis, five-patient case series, Radiation Oncology, October 2025

If additional blood support is required, its iron contribution belongs in subsequent iron management. The immediate neurological problem can take priority without removing long-term iron assessment from the care plan. Chelation decisions still depend on iron measurements, organ function, and treatment tolerance; a patient should not increase a chelator simply by counting additional transfusion visits. Porter, Wood and Coates: Iron Overload and Chelation, TIF 2025

Review medication rather than copying a published combination

Some treatments used for anemia have relevant precautions in this setting. The current US luspatercept label includes a warning about EMH masses and complications from compression. A person receiving that medicine should report new back pain, weakness, or neurological symptoms promptly to the prescribing team. The clinician must decide whether interruption or another change is needed. DailyMed: REBLOZYL prescribing information, updated February 2026

Hydroxyurea or corticosteroids appearing in a case report do not become standard home treatment for every person with thalassemia. Bring an accurate list of medicines, start dates, actual use, and recent changes. It helps clinicians distinguish the purpose of each drug and consider whether the current symptoms relate to the lesion, another condition, or treatment. Do not start a reported combination while awaiting specialist assessment.

Arranging an assessment in China

For a medically stable person considering care in China, the practical question is whether the receiving service can coordinate hematology, radiation oncology, and spinal or neurosurgical expertise when necessary. China's national thalassemia prevention and control network is an official starting point for understanding participating institutions. Membership does not establish that every center can immediately manage an intraspinal lesion, accept an international patient, or provide an available bed. Confirm the actual receiving pathway with the institution. 国家卫生健康委：全国地中海贫血防控协作网，2023TIF 2025: Multidisciplinary Care and Reference Centres

Send original MRI files, a dated symptom history, neurological examination findings, transfusion and antibody records, relevant bone assessments, and any previous radiation plan. A translated phrase such as paraspinal mass is insufficient for a usable treatment assessment. If weakness or bladder and bowel symptoms are progressing, stabilize the urgent problem locally before considering international transfer. Travel arrangements must follow the clinical situation rather than determine it.

Judge recovery through function as well as imaging

Pain, strength, sensation, and the size of a residual mass need not change at the same pace. Ask for separate plans for clinical examination, repeat imaging, and rehabilitation. Persistent weakness may require a supervised assessment of mobility and equipment; intensive self-directed exercise is not a safe way to test whether the cord has recovered. Ordinary thalassemia monitoring must also remain scheduled. TIF 2025: Summary of Monitoring RecommendationsTIF 2025: Lifestyle and Quality of Life

Before discharge, establish which symptoms require immediate help, where planned reassessment will happen, and who will combine the radiation findings with the hematology review. New symptoms after an earlier response require a fresh evaluation. A previous benefit from radiation does not mean the same field or dose can simply be repeated, and a new lesion elsewhere is a reason to review the broader disease management as well as local options.

References

Related guides